
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Expand your mAb NBE candidate pipeline numbers by leveraging ProtaGene's flexible analytical capacities. Get a complete overview of ProtaGene's end to end services.





